ASCO 2023: Ribociclib Plus Endocrine Therapy Improves Survival in Patients With HR-Positive, HER2-Negative Breast Cancer
Addition of ribociclib to adjuvant endocrine therapy showed improvement in invasive disease-free survival at three years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.